Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature
Presently, the use of convalescent plasma and hyperimmunoglobulin obtained from individuals who have recovered from coronavirus disease 2019 (COVID-19) has proved to potentially provide passive antibody-based immunity, thereby leading to several clinical trials to develop an immune-based COVID-19 tr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/9/1826 |
| _version_ | 1827681016924340224 |
|---|---|
| author | Sunha Choi Soyoon Hwang Kitae Kwon |
| author_facet | Sunha Choi Soyoon Hwang Kitae Kwon |
| author_sort | Sunha Choi |
| collection | DOAJ |
| description | Presently, the use of convalescent plasma and hyperimmunoglobulin obtained from individuals who have recovered from coronavirus disease 2019 (COVID-19) has proved to potentially provide passive antibody-based immunity, thereby leading to several clinical trials to develop an immune-based COVID-19 treatment. However, the therapeutic efficacy of hyperimmunoglobulin in critically ill patients with COVID-19 remains unknown. On 23 October 2020, we first administered GC5131 in a compassionate-use program to critically ill patients at the Kyungpook National University, Chilgok Hospital, Korea. Since then, five more critically ill patients were treated with GC5131 in this compassionate-use program in our hospital up until 17 December 2020. We retrospectively reviewed the clinical responses of six critically ill patients diagnosed with COVID-19 who received the hyperimmunoglobulin concentrate, GC5131, which was produced by the Green Cross Corporation. After the administration of GC5131, five patients died due to an exacerbation of COVID-19 pneumonia. GC5131 was ineffective when administered to critically ill patients with COVID-19. Nevertheless, we propose that to expect a therapeutic effect from GC5131, it should be administered as early as possible to avoid the excessive inflammatory response phase in patients with severe and advanced COVID-19 infection. This step was difficult to achieve in the real world due to the time required for decision making and the process of the compassionate-use program. |
| first_indexed | 2024-03-10T07:08:26Z |
| format | Article |
| id | doaj.art-2ab4a5ba64cf483e974da2a895fd9300 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T07:08:26Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-2ab4a5ba64cf483e974da2a895fd93002023-11-22T15:38:34ZengMDPI AGViruses1999-49152021-09-01139182610.3390/v13091826Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of LiteratureSunha Choi0Soyoon Hwang1Kitae Kwon2Division of Pulmonary Disease, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 47404, KoreaDivision of Infectious Diseases, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 47404, KoreaDivision of Infectious Diseases, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 47404, KoreaPresently, the use of convalescent plasma and hyperimmunoglobulin obtained from individuals who have recovered from coronavirus disease 2019 (COVID-19) has proved to potentially provide passive antibody-based immunity, thereby leading to several clinical trials to develop an immune-based COVID-19 treatment. However, the therapeutic efficacy of hyperimmunoglobulin in critically ill patients with COVID-19 remains unknown. On 23 October 2020, we first administered GC5131 in a compassionate-use program to critically ill patients at the Kyungpook National University, Chilgok Hospital, Korea. Since then, five more critically ill patients were treated with GC5131 in this compassionate-use program in our hospital up until 17 December 2020. We retrospectively reviewed the clinical responses of six critically ill patients diagnosed with COVID-19 who received the hyperimmunoglobulin concentrate, GC5131, which was produced by the Green Cross Corporation. After the administration of GC5131, five patients died due to an exacerbation of COVID-19 pneumonia. GC5131 was ineffective when administered to critically ill patients with COVID-19. Nevertheless, we propose that to expect a therapeutic effect from GC5131, it should be administered as early as possible to avoid the excessive inflammatory response phase in patients with severe and advanced COVID-19 infection. This step was difficult to achieve in the real world due to the time required for decision making and the process of the compassionate-use program.https://www.mdpi.com/1999-4915/13/9/1826COVID-19immunoglobulinconvalescenceplasmaclinical effectiveness |
| spellingShingle | Sunha Choi Soyoon Hwang Kitae Kwon Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature Viruses COVID-19 immunoglobulin convalescence plasma clinical effectiveness |
| title | Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature |
| title_full | Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature |
| title_fullStr | Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature |
| title_full_unstemmed | Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature |
| title_short | Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature |
| title_sort | compassionate use of gc5131 hyperimmunoglobulin therapy in critically ill patients diagnosed with covid 19 a case series and review of literature |
| topic | COVID-19 immunoglobulin convalescence plasma clinical effectiveness |
| url | https://www.mdpi.com/1999-4915/13/9/1826 |
| work_keys_str_mv | AT sunhachoi compassionateuseofgc5131hyperimmunoglobulintherapyincriticallyillpatientsdiagnosedwithcovid19acaseseriesandreviewofliterature AT soyoonhwang compassionateuseofgc5131hyperimmunoglobulintherapyincriticallyillpatientsdiagnosedwithcovid19acaseseriesandreviewofliterature AT kitaekwon compassionateuseofgc5131hyperimmunoglobulintherapyincriticallyillpatientsdiagnosedwithcovid19acaseseriesandreviewofliterature |